Abeona Therapeut Stock Price, News & Analysis

Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the presentation of data from its pivotal Transpher A study for ABO-102 gene therapy targeting Sanfilippo syndrome type A at the 14th International Congress of Inborn Errors of Metabolism (ICIEM) from November 21-23, 2021. The interim results will be shared by Dr. Nicholas Smith, highlighting a positive correlation between cognitive functioning measures in young children. This event underscores Abeona's commitment to advancing its gene therapy offerings for serious diseases.

Abeona Therapeutics Inc. (Nasdaq: ABEO) announced participation of CEO Vish Seshadri at the Jefferies London Healthcare Conference from November 16-19, 2021. A pre-recorded webcast will be accessible on their investor webpage starting November 18, 2021. Abeona, a clinical-stage biopharmaceutical company, focuses on gene and cell therapies for serious diseases, including its Phase 3 investigational therapy for epidermolysis bullosa and gene therapies for Sanfilippo syndromes. The company operates a cGMP manufacturing facility for its therapies.

Abeona Therapeutics Inc. (Nasdaq: ABEO) reported Q3 2021 results and progress on key projects. The Phase 3 VIITAL™ study for EB-101 is on track to finish patient enrollment in Q1 2022, with top-line data expected by Q3 2022. The company anticipates submitting Biologics License Applications (BLA) for both EB-101 and ABO-102 in late 2022 to early 2023. A settlement with REGENXBIO has been reached, resolving a dispute and allowing resource focus on pipeline advancement. As of September 30, 2021, cash was $67 million, with a net loss of $7 million for the quarter.

Abeona Therapeutics Inc. (Nasdaq: ABEO) announced that CEO Vish Seshadri, Ph.D., M.B.A., will present at the Jefferies Gene Therapy/Editing Summit on October 27, 2021, at 3:30 p.m. ET. The presentation will be available live and archived on the company’s investor website. Abeona is focused on gene and cell therapies for serious diseases, with key projects including the Phase 3 autologous gene-corrected therapy EB-101 for epidermolysis bullosa, and AAV-based therapies for Sanfilippo syndrome types A and B, currently in Phase 1/2 development.

Abeona Therapeutics (Nasdaq: ABEO) announced two upcoming presentations of clinical data at scientific congresses in October 2021. The first presentation will showcase long-term wound healing and pain relief data from the Phase 1/2a EB-101 trial at the PeDRA Annual Conference on October 14-15, 2021. The second presentation will discuss interim results from the pivotal trial of investigational gene therapy ABO-102 in MPS IIIA at the ESGCT Congress from October 19-22, 2021. These events highlight Abeona's advancements in gene therapy for rare diseases.

Abeona Therapeutics Inc. (Nasdaq: ABEO) announced the appointment of Jon Voss as Vice President, Head of Quality. Voss, previously a consultant, brings over 30 years of quality experience in gene therapy and biopharmaceuticals, having held senior roles at Cellectis, Sarepta Therapeutics, and Genzyme. His leadership is expected to enhance Abeona’s quality processes as the company prepares for two Biologics License Application submissions for its therapies, EB-101 and ABO-102, currently in pivotal studies.

Abeona Therapeutics Inc. announced significant leadership changes, including the retirement of Steven Rouhandeh as Chairman and the appointment of Michael Amoroso as his successor, effective October 15, 2021. Dr. Vishwas Seshadri will become CEO on the same date, enhancing leadership direction as the company prepares for Biologics License Application submissions for its gene therapies, EB-101 and ABO-102. Additional promotions within the executive team include Brendan O'Malley as General Counsel and Brian Kevany as Chief Technical Officer, among others, to support growth and operational capacity.

Abeona Therapeutics, a leader in gene and cell therapy, announced participation in several virtual investor conferences. Key events include Citi’s 16th Annual BioPharma Virtual Conference (Sept. 8-10), H.C. Wainwright 23rd Annual Global Investment Conference (Sept. 13-15), SVB Leerink CybeRx Series (Sept. 22-23), and Cantor Fitzgerald Virtual Global Healthcare Conference (Sept. 30). Presentations will be available on their website, with webcasts accessible for 90 days post-event. Notable products in development include EB-101 for recessive dystrophic epidermolysis bullosa and AAV-based gene therapies for Sanfilippo syndrome.

Abeona Therapeutics (Nasdaq: ABEO) appointed Edward Carr as Chief Financial Officer, effective immediately. Carr has been with the company since 2018, serving as Chief Accounting Officer. The company's CEO, Michael Amoroso, expressed confidence in Carr’s leadership to drive clinical and regulatory goals while enhancing long-term success. Abeona is focused on gene and cell therapies, with clinical programs including EB-101 for epidermolysis bullosa in Phase 3, and AAV-based therapies for Sanfilippo syndrome in Phase 1/2.